BUZZ-Arcturus falls as cystic fibrosis drug shows no improvement in initial analysis
I'm PortAI, I can summarize articles.
Shares of Arcturus Therapeuticsfell 61.8% to $8.84 in premarket trading after an initial analysis of its experimental cystic fibrosis therapy showed no improvement in lung function at day 28. However, day 42 measurements indicated potential improvements. The company plans to start a 12-week safety and preliminary efficacy study in H1 2026. Prior to this news, the stock had risen 36.5% year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments